お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
335689

放射線皮膚障害:パイプライン製品の分析

Radiodermatitis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 57 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
放射線皮膚障害:パイプライン製品の分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 57 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚障害は、放射線を原因とする皮膚の炎症です。分割照射の範囲、エネルギーの種類、照射量といった治療の要素によって、患者の肌に現れる症状は多様です。遺伝的要因、皮膚の状態、合併症、栄養状態、年齢、人種、服薬、日光への曝露、喫煙といった要因が放射線皮膚障害の進行に大きな役割を果たしています。

当レポートでは、放射線皮膚障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

放射線皮膚障害の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

放射線皮膚障害:企業で開発中の治療薬

放射線皮膚障害:大学/機関で研究中の治療薬

放射線皮膚障害:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

放射線皮膚障害:企業で開発中の製品

放射線皮膚障害:大学/機関で研究中の製品

放射線皮膚障害の治療薬開発に従事している企業

  • ProCertus BioPharm Inc.
  • Reata Pharmaceuticals, Inc.
  • SK Chemicals Co., Ltd.
  • Vida Therapeutics Inc.

放射線皮膚障害:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

放射線皮膚障害:最近のパイプライン動向

放射線皮膚障害:休止中のプロジェクト

放射線皮膚障害:開発が中止された製品

放射線皮膚障害:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Radiodermatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Radiodermatitis - Pipeline by Amryt Pharma Plc, H1 2020
  • Radiodermatitis - Pipeline by BioCurity Pharmaceuticals Inc, H1 2020
  • Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020
  • Radiodermatitis - Pipeline by Jay Pharma Inc, H1 2020
  • Radiodermatitis - Pipeline by KannaLife Sciences Inc, H1 2020
  • Radiodermatitis - Pipeline by Matrix Biomed Inc, H1 2020
  • Radiodermatitis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
  • Radiodermatitis - Pipeline by Regeneus Ltd, H1 2020
  • Radiodermatitis - Pipeline by RepoCeuticals ApS, H1 2020
  • Radiodermatitis - Pipeline by Sunny Pharmtech Inc, H1 2020
  • Radiodermatitis - Dormant Projects, H1 2020
  • Radiodermatitis - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Radiodermatitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12274IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Radiodermatitis - Overview
  • Radiodermatitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Radiodermatitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Radiodermatitis - Companies Involved in Therapeutics Development
  • Amryt Pharma Plc
  • BioCurity Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Jay Pharma Inc
  • KannaLife Sciences Inc
  • Matrix Biomed Inc
  • Noveome Biotherapeutics Inc
  • Regeneus Ltd
  • RepoCeuticals ApS
  • Sunny Pharmtech Inc
  • Radiodermatitis - Drug Profiles
  • Biologic for Dermatology and Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • birch bark extract - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cannabidiol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cerium oxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FP-045 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KLS-13019 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • phenylbutyrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RS-9 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ST-266 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tempol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZM-241385 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Radiodermatitis - Dormant Projects
  • Radiodermatitis - Discontinued Products
  • Radiodermatitis - Product Development Milestones
  • Featured News & Press Releases
  • Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.